The 12 most recent market catalysts affecting $CVRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 55
CVRx Appoints John Landry CFO, Effective Oct. 12, Succeeding Jared Oasheim
CVRx has announced a new Chief Financial Officer, John Landry, who will take over from Jared Oasheim. This is a planned succession, with Oasheim's resignation previously disclosed,…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 85
CVRx shares are trading higher after the company announced that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy.
The news that Devoted Health, a significant Medicare Advantage provider, will cover Barostim therapy is a major positive for CVRx. This decision validates the therapy's efficacy an…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 85
CVRx Shareholder Urges Board To Launch Sale Process To Unlock Barostim’s Strategic Value
Jorey Chernett, a beneficial owner of over 5.5% of CVRx, has delivered a letter to the Board demanding an immediate and formal sale process. This is a significant activist investor…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 75
CVRx Announces Devoted Health Issued Medicare Advantage Coverage Policy For Barostim Effective July 17
The headline indicates a significant positive development for CVRx. Devoted Health's decision to cover Barostim through its Medicare Advantage plans effective July 17th means a lar…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 75
CVRx shares are trading lower after Cantor Fitzgerald lowered its price target on the stock from $13 to $5.
The significant reduction in CVRx's price target from $13 to $5 by Cantor Fitzgerald is a major negative catalyst for the company. Such a drastic cut, representing a 61.5% decrease…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 65
Cantor Fitzgerald Maintains Overweight on CVRx, Lowers Price Target to $5
Cantor Fitzgerald analyst Sarah James maintained an 'Overweight' rating on CVRx, indicating a continued positive long-term outlook for the company. However, the accompanying reduct…
Aug 8, 2026
Corporate Catalyst
Bearish
Impact 65
Lake Street Downgrades CVRx to Hold, Lowers Price Target to $3.5
Lake Street analyst Frank Takkinen downgraded CVRx from a 'Buy' to a 'Hold' rating and drastically cut the price target from $14 to $3.5. This move signals a significant loss of co…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 85
CVRx shares are trading lower after the company reported worse-than-expected Q2 EPS results and lowered its FY2026 sales guidance.
This headline represents a significant corporate catalyst, directly impacting CVRx's stock performance. The combination of a Q2 earnings miss and a reduced long-term sales forecast…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 95
CVRx Stock Is Falling Overnight: Here's What's Driving the Move
CVRx experienced a massive overnight stock drop of over 45% because it drastically cut its full-year revenue guidance for 2026. This negative revision, from a company that had just…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
CVRx shares are trading lower after the company reported worse-than-expected Q2 EPS results and lowered its FY2026 sales guidance.
This headline represents a significant corporate catalyst, directly impacting CVRx's stock performance. The combination of a quarterly earnings miss and a reduced long-term sales f…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
CVRx Lowers FY2026 Sales Guidance from $63.000M-$67.000M to $58.000M-$60.000M vs $65.340M Est
CVRx's decision to lower its FY2026 sales guidance by $5M-$7M is a significant negative development for the company. This revised outlook is now considerably below the prior analys…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
CVRx Q2 EPS $(0.53) Misses $(0.52) Estimate, Sales $15.705M Beat $15.549M Estimate
This headline indicates a mixed bag for CVRx. While the sales beat is a positive sign, suggesting continued market adoption of their medical devices, the EPS miss raises concerns a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.